Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) reported Q4 CY2024 results topping the market’s revenue ...

Q4 2024 Earnings Call Transcript February 26, 2025 Operator: Good morning. Welcome to the Lantheus Fourth Quarter and Full ...

Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) jumped 19.8% in the morning session after the company ...

Prostate imaging drug Pylarify has become the first radiodiagnostic blockbuster, achieving over $1 billion in sales for 2024. The addressable market continues to expand.

Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) will be reporting earnings tomorrow before market hours. Here’s ...

In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Lantheus (LNTH – Research Report), with a price ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lantheus (LNTH – Research Report) and Argenx Se ...

Lantheus Holdings Inc (($LNTH)) has held its Q4 earnings call. Read on for the main highlights of the call. Lantheus Holdings Inc. recently held ...

Lantheus Holdings shares rose after its adjusted earnings for the fourth quarter and 2025 outlook estimates were higher than expected. The stock climbed 20%, to $96.36. The stock has gained about half ...

Welcome to the Lantheus Fourth Quarter and Full Year 2024 Conference Call. [Operator Instructions]. This call is being recorded and a replay will be available in the Investors section of the company's ...

Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient ...

Explore the exciting world of Lantheus Holdings (NASDAQ: LNTH) with our expert analysts in this Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...